Tongling Jieya Biologic Technology Co., Ltd. Class A

Tongling Jieya Biologic Technology Co., Ltd. Class A

SSZSE:301108
39.19
CNY
-1.11
(-2.75%)
0.44EPS
117.28P/E
5.77BMarket Cap
Apr 15Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.84
3.33
3.26
8.72
11.25
5.88
5.48
4.78
6.79
7.01
Basic EPS, GAAP
0.3
0.68
0.8
2.11
2.51
1.24
1.01
0.17
0.68
0.44
Free Cash Flow per Basic Share
0.2
0.32
0.91
0.99
1.46
2.37
-0.01
-0.18
-2.37
- -
Dividend per Share
0.02
- -
0.36
0.04
- -
0.54
0.36
0.25
0.17
0.26
Book Value per Share
3.96
5.31
6.2
5.18
14.89
15.65
16.35
16.07
16.72
16.96
Tangible Book Value per Share
3.41
4.78
5.54
4.82
14.64
15.4
16.04
15.77
16.16
16.34
Basic Weighted Avg Shares
86
85
85
85
88
113
114
114
114
125
Sales/Revenue/Turnover
243
283
277
743
984
667
623
547
772
875
Operating Margin (%)
13.15
23.53
26.77
29.86
25.75
21.94
17
5.93
13.13
12.54
Depreciation Expense
12
14
14
17
31
34
39
47
52
- -
Net Income, GAAP
26
58
68
180
220
141
115
19
77
55
Effective Tax Rate (%)
11.48
12.56
13.3
13.25
12.63
13.07
15.16
23.75
10.6
2.69
Profit Margin (%)
10.57
20.36
24.55
24.18
22.35
21.15
18.5
3.56
10.01
6.23
Working Capital
67
129
154
222
1,451
1,279
1,346
1,509
1,164
1,035
LT Debt
- -
- -
5
22
35
19
10
1
28
24
Total Equity
169
226
264
442
1,693
1,779
1,859
1,827
1,882
1,909
Return on Invested Capital (%)
- -
31.21
29.83
49.03
19.72
8.42
6.2
1.01
4.16
2.78
Return on Capital (%)
- -
29.18
27.5
47.04
19.76
8.05
6.33
1.1
4.18
2.88
Return on Common Equity (%)
- -
29.18
27.77
50.91
20.61
8.12
6.33
1.06
4.17
2.89

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
72
111
110
LT Borrowings
- -
- -
- -
LT Finance Leases
26
27
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
113
113
113
Market Capitalization
3,314
2,655
5,766

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,569
1,674
1,628
Cash, Cash Equivalents & STI
968
1,046
1,006
Accounts Receivable, Net
203
213
222
Inventories
87
102
108
Total Current Liabilities
429
585
593
Payables & Accruals
- -
- -
- -
ST Debt
72
111
110
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
58.87%
3%
Free Cash Flow
- -
501.65%
1,173%
Net Income, GAAP
- -
36.43%
296.97%
Sales/Revenue/Turnover
- -
4.51%
41.02%
Total Cash Common Dividend
- -
4,568.06%
-33.84%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
130
155
123
139
547
2025
124
186
- -
207
772
2026
192
227
249
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.11
0.07
-0.14
0.17
2025
0.13
0.2
- -
0.08
0.68
2026
0.09
0.28
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.25
2025
- -
- -
- -
- -
0.17
2026
0.01
0.16
0.09
- -
- -

Company Description

CEO
Ying Chuan Cai
Full Time Employees
647
Sector
Consumer non-durables
Industry
Household/Personal care
Address
Tongling China
IPO Date
Dec 3, 2021
Business
Tongling Jieya Biologic Technology Co., Ltd. is a China-based company primarily engaged in the research, development, manufacture, and sale of wet wipes, hygiene products, and personal care cosmetics. Founded in 1999 and headquartered in Tongling, Anhui Province, the company operates principally as an original design manufacturer (ODM) and original equipment manufacturer (OEM) for leading global and domestic consumer goods brands. Tongling Jieya categorizes its core offerings into systematic product segments: baby care wipes, including infant hand and mouth wipes, nourishing baby wipes, and diaper area cleansing wipes; personal hygiene and cosmetic wipes, encompassing makeup remover towelettes, facial cleansing cloths, feminine hygiene wipes, and flushable moist toilet tissues; functional and household cleaning wipes, comprising antibacterial disinfectant wipes, multi-surface cleaning wipes, kitchen degreasing wipes, and pet grooming wipes; medical care wipes, including clinical-grade surface sanitizing wipes and patient skin cleansing wipes; and skincare and cosmetic formulations, such as facial sheet masks, cleansing liquids, toners, serums, and hydrating lotions. The company serves consumer, healthcare, and retail sectors across domestic Chinese markets and exports internationally to regions including North America, Europe, Oceania, and Southeast Asia. In recent operational and strategic developments, Tongling Jieya has accelerated the diversification of its product portfolio by expanding beyond conventional wet wipes into high-value beauty and skincare manufacturing, deploying specialized cleanroom production workshops and advanced formulation processing lines. To meet global environmental regulations and consumer sustainability demands, the company has launched eco-friendly product series utilizing 100% biodegradable non-woven fabrics, flushable plant-based substrates, and plastic-free fibers. Furthermore, Tongling Jieya has upgraded its smart manufacturing infrastructure with automated high-speed production and packaging systems, expanded its microbiological testing and research and development facilities, and engaged in strategic healthcare and supply chain investment initiatives to enhance operational scalability and formulation technology.